Philip Young, former chief executive of Osteologix Inc, has been appointed president and CEO of AmpliPhi Biosciences Corporation of Seattle, Washington and Colworth, UK. AmpliPhi Biosciences is working in the area of bacteriophage-based anti-bacterial therapies. Prior to joining Osteologix, Mr Young held a number of senior executive positions with publicly traded biotechnology companies including Insmed Inc and Neurex Pharmaceuticals, which is now part of Elan Corporation.
Copyright 2011 Evernow Publishing Ltd